Washington Trust Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Washington Trust Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-364	Closed	-$1.89K	–	690
2024 Q3	$1.89K	Hold	364	–	–	﹤0.01%	638
2024 Q2	$936	Hold	364	–	–	﹤0.01%	652
2024 Q1	$1.79K	Hold	364	–	–	﹤0.01%	640
2023 Q4	$3.2K	Buy	364 +120	+49%	+$983	﹤0.01%	620
2023 Q3	$2.8K	Hold	244	–	–	﹤0.01%	615
2023 Q2	$6.18K	Hold	244	–	–	﹤0.01%	519
2023 Q1	$7.86K	Buy	244 +47	+24%	+$1.47K	﹤0.01%	537
2022 Q4	$3.64K	Hold	197	–	–	﹤0.01%	652
2022 Q3	$5K	Hold	197	–	–	﹤0.01%	732
2022 Q2	$3K	Hold	197	–	–	﹤0.01%	853
2022 Q1	$4K	Hold	197	–	–	﹤0.01%	876
2021 Q4	$3K	Buy	+197	New	+$3.28K	﹤0.01%	947

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Washington Trust Advisors's RVNC Position: Q4 2024 in Review

Washington Trust Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 364 shares — an estimated $1.89K sold.

Washington Trust Advisors first reported a position in RVNC in Q4 2021 and held it in 12 quarters. The position peaked at $7.86K in Q1 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

Washington Trust Advisors reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
Washington Trust Advisors sold 364 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $1.89K.
Washington Trust Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 12 quarters.
Washington Trust Advisors's Revance Therapeutics, Inc. position peaked at $7.86K in Q1 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Washington Trust Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.